Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 85, Issue 6, Pages 1077-1084Publisher
WILEY
DOI: 10.1002/jmv.23546
Keywords
adenovirus; vaccine; vector
Categories
Ask authors/readers for more resources
Replication-defective adenoviruses have been utilized as candidate vaccine vectors. However, clinical application of the best-studied human adenovirus type-5 (AdHu5) is limited by the high prevalence of preexisting neutralizing antibodies resulting from natural infection. Therefore, rare adenovirus serotypes, such as human adenovirus type-26 (AdHu26) and chimpanzee adenovirus type-68 (AdC68), have been employed as substitutes for AdHu5. However, few studies have described the epidemiology of pre-existing immunity to these adenoviruses in China. Thus, 1,154 participants from six regions in China were examined to assess the presence of neutralizing antibodies against AdHu5, AdHu26, and AdC68. The seroprevalence rates of neutralizing antibodies were as follows: AdHu5, 73.1% (844/1,154) (95% confidence interval: 70.575.6%); AdHu26, 35.3% (407/1,154) (95% confidence interval: 32.638.1%); and AdC68, 12.7% (147/1,154) (95% confidence interval: 10.914.8%), respectively. The most frequently detected and highest titer antibodies were specific for AdHu5. The results indicate that AdHu26 and AdC68 serve as more suitable vaccine vectors than AdHu5. J. Med. Virol. 85: 10771084, 2013. (c) 2013 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available